Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy

BJU International

Volumn 113, Issue 1, 2014, Pages 70-76

  Shariat, Shahrokh F ^a   Passoni, Niccolo ^b   Bagrodia, Aditya ^c   Rachakonda, Varun ^c   Xylinas, Evanguelos ^b   Robinson, Brian ^b   Kapur, Payal ^d   Sagalowsky, Arthur I ^c   Lotan, Yair ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

biomarkers; bladder cancer; prognosis; prospective; upstaging

Indexed keywords

CYCLIN E; CYCLIN E1; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P27; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG;

AGED; AREA UNDER THE CURVE; BLADDER CANCER; CANCER STAGING; CANCER SURGERY; CANCER UPSTAGING; CONTROLLED STUDY; CYSTECTOMY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVIEW; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

BIOMARKERS; BLADDER CANCER; PROGNOSIS; PROSPECTIVE; UPSTAGING;

AGED; AREA UNDER CURVE; CARCINOMA, TRANSITIONAL CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYSTECTOMY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84890486719     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12343     Document Type: Review

References (46)

1. Svatek RS, Shariat SF, Novara G, et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 2011; 107: 898-904
2. Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007; 51: 137-149
3. Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011; 59: 1009-1018
4. Green DA, Durand M, Gumpeni N, et al. Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques. BJU Int 2012; 110: 1463-1470
5. Karakiewicz PI, Shariat SF, Palapattu GS, et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol 2006; 50: 1254-1260
6. Green DA, Rink M, Hansen J, et al. Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. BJU Int 2013; 111: 404-411
7. Shariat SF, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI,. Nomograms for bladder cancer. Eur Urol 2008; 54: 41-53
8. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J,. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-314
9. Fritsche HM, Burger M, Svatek RS, et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 2010; 57: 300-309
10. Bensalah K, Montorsi F, Shariat SF,. Challenges of cancer biomarker profiling. Eur Urol 2007; 52: 1601-1609
11. Shariat SF, Canto EI, Kattan MW, Slawin KM,. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol 2004; 6: 58-72
12. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y,. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 2006; 37: 1568-1576
13. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y,. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol 2007; 25: 468-475
14. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y,. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007; 177: 481-487
15. Shariat SF, Bolenz C, Godoy G, et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 2009; 182: 78-84
16. Shariat SF, Bolenz C, Karakiewicz PI, et al. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int 2010; 105: 489-495
17. Shariat SF, Chade DC, Karakiewicz PI, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010; 183: 68-75
18. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Combination of cell cycle regulating bio-markers improves prognosis in patients with organ-confined urothelial carcinoma at radical cystectomy. J Urol 2008; 179: 578
19. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008; 112: 315-325
20. Shariat SF, Lotan Y, Karakiewicz PI, et al. p53 Predictive value for pT1-2 N0 disease at radical cystectomy. J Urol 2009; 182: 907-913
21. Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y,. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007; 20: 445-459
22. Shariat SF, Chromecki TF, Cha EK, et al. Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol 2012; 187: 457-462
23. Shariat SF, Lotan Y, Vickers A, et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 2010; 28: 389-400
24. Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998; 58: 1090-1094
25. Cordon-Cardo C, Zhang ZF, Dalbagni G, et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997; 57: 1217-1221
26. Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004; 22: 1014-1024
27. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004; 22: 1007-1013
28. Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP,. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 2003; 61: 1140-1145
29. Karam JA, Lotan Y, Karakiewicz PI, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007; 8: 128-136
30. Rink M, Chun FK, Robinson B, et al. Tissue-based molecular markers for renal cell carcinoma. Minerva Urol Nefrol 2011; 63: 293-308
31. Benedict WF, Lerner SP, Zhou J, Shen X, Tokunaga H, Czerniak B,. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 1999; 18: 1197-1203
32. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993; 85: 53-59
33. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331: 1259-1264
34. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG,. p53 and treatment of bladder cancer. Nature 1997; 385: 123-125
35. Malats N, Bustos A, Nascimento CM, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005; 6: 678-686
36. Stein JP, Ginsberg DA, Grossfeld GD, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998; 90: 1072-1079
37. Korkolopoulou P, Christodoulou P, Konstantinidou AE, Thomas-Tsagli E, Kapralos P, Davaris P,. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Hum Pathol 2000; 31: 751-760
38. Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y,. Cooperative effect of cell cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007; 20: 445-459
39. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y,. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006; 12: 7369-7373
40. Margulis V, Lotan Y, Karakiewicz PI, et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 2009; 101: 114-119
41. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA,. Evaluating the yield of medical tests. JAMA 1982; 247: 2543-2546
42. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387
43. Shariat SF, Weizer AZ, Green A, et al. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology 2000; 56: 735-740
44. Rink M, Cha EK, Green D, et al. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep 2012; 13: 122-135
45. Kamat AM, Hegarty PK, Gee JR, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, Diagnosis, and Molecular Markers. Eur Urol 2013; 63: 4-15
46. Sonpavde G, Shariat SF,. Preoperative chemotherapy for bladder cancer: a standard waits to be optimally deployed. Cancer 2012; 118: 8-11